Medical Treatment Update for Eisenmenger Syndrome
Author Information
Author(s): Mebus Siegrun, Schulze-Neick Ingram, Oechslin Erwin, Niwa Koichiro, Trindade Pedro T, Hager Alfred, Hess John, Kaemmerer Harald
Primary Institution: Deutsches Herzzentrum München, Technische Universität München
Conclusion
Bosentan appears to be safe and effective for treating pulmonary arterial hypertension related to Eisenmenger syndrome, improving exercise capacity and hemodynamics.
Supporting Evidence
- Bosentan has been shown to improve exercise capacity and hemodynamics in Eisenmenger patients.
- The BREATHE-5 study demonstrated significant improvements in patients treated with bosentan.
- Long-term follow-up indicated that improvements in exercise capacity were maintained for up to 40 weeks.
Takeaway
Eisenmenger syndrome is a serious heart condition, and new treatments like bosentan can help patients feel better and live longer.
Methodology
The study reviewed various treatment options and their effects on patients with Eisenmenger syndrome.
Potential Biases
There is a risk of bias due to the reliance on uncontrolled studies and anecdotal evidence.
Limitations
The data is limited due to small patient numbers and a lack of randomized controlled studies.
Participant Demographics
The study focuses on adult patients with Eisenmenger syndrome.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website